The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro ...

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they ...

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...

Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug ...

Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular ...

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy innovation supports long-term health. By combining lower pricing, direct-to ...

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of ...

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of ...